Since the 2002 launch of Humira, many products have entered the rheumatoid arthritis (RA) market, but the majority of sales still belongs to the big three anti-TNFs (Enbrel, Humira and Remicade).

The tumor necrosis factor inhibitors Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab) and Cimzia (certolizumab pegol) are being investigated by the US Food and Drug Administration ...

Several Humira-referenced biosimilars were approved ... Perhaps a prime example of a very lengthy monopoly is the arthritis drug Enbrel (etanercept), which was first approved by the FDA in 1998.

Strong progress has already been seen on UK uptake of rituximab (MabThera), infliximab (Remicade) and etanercept (Enbrel) biosimilars, with the latter two rivalling Humira in indications such as ...

Enbrel (etanercept) from Amgen of Thousand Oaks, California, Remicade (infliximab), from Centocor of Horsham, Pennsylvania and Humira (adalimumab), from Abbott of Abbott Park, Illinois.